In the first in a series of ‘In Conversation’ films, we bring together science and tech as Research Scientist Megan Egbert and Machine Learning Engineer Jack L. discuss their work tackling fundamental biological problems at scale by employing machine learning for in silico drug design at Isomorphic Labs. Interested in getting involved? Find our current openings on our website: bit.ly/3wuRQbL #AI #drugdiscovery #machinelearning
Isomorphic Labs
Biotechnology Research
We are reimagining the entire drug discovery process from first principles with an AI-first approach.
About us
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.
- Website
-
https://www.isomorphiclabs.com/
External link for Isomorphic Labs
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
Get directions
London, GB
Employees at Isomorphic Labs
Updates
-
Our Chief AI Officer, Max Jaderberg, joined the Sana AI Summit a few weeks ago to discuss how AI can help us to reimagine drug design. Catch up with the discussion now if you missed it: bit.ly/45873Nm
Solving deep societal problems with AI is a long-term game. It requires vision, patience, and the ability to translate academic theory into real-world applications. Max Jaderberg and Tuomas Sandholm are shining examples. Max leads the research and application of machine learning for drug discovery at Isomorphic Labs. Last month, Google DeepMind and Isomorphic Labs announced AlphaFold 3, a revolutionary new model that can predict the structure and interactions of all life's molecules with unprecedented accuracy. Tuomas is the architect of Libratus, the first and only AI to beat top human players at Texas hold’em poker. Alongside his research into and application of game theory, Tuomas has focused on medicine. Since 2010, his algorithms have run the USA's national kidney exchange and led to over 10,000 life saving kidney transplants worldwide. Here's a slice of what Max and Tuomas had to say about AI's impact on science and knowledge. Link to the full fireside in comments.
-
-
-
-
-
+4
-
-
Our General Counsel Sarah Korman joins a panel discussion with Hans Sauer, Ryan Abbott and Andrei Iancu at #BIO2024. The panel will explore state-of-the-law and policy on AI-generated inventions globally and discuss how biopharma can protect AI inventions and the future of AI-powered innovation.
-
-
Can we use artificial intelligence to design new drugs? Our Chief Scientific Officer, Miles Congreve, will be delivering the keynote address at Galien Forum UK on May 30th. If you’re attending, join him and learn more about how we’re doing it at Isomorphic Labs. #AI #machinelearning #drugdiscovery
-
-
Join our CTO Sergei Yakneen at #VivaTech in Paris, May 22nd, 2.40 - 3.15pm CEST as he explores the potential for groundbreaking advancements in healthcare enabled by AI alongside Marion Classe, Alex Devereson, and Julia Hawkins. #AI #machinelearning #drugdiscovery
-
-
Join our President, Colin Murdoch, today at STAT Breakthrough Summit at 9.50am PDT to hear more about our work applying AI breakthroughs like #AlphaFold 3 to drug design.
-
-
Tomorrow, our Chief AI Officer Max Jaderberg will be at the Sana AI Summit, alongside Tuomas Sandholm, exploring the future of science and knowledge. Join the waitlist and register to receive recordings from the event: t.co/CRsVxTdsvB
-
-
Alongside Google DeepMind, we’re excited to introduce #AlphaFold 3 – an AI model which goes beyond protein structure prediction to predict how proteins interact with other important biomolecules, including DNA, RNA and ligands, with unprecedented accuracy. This builds a much richer, more comprehensive picture of biological interactions to fuel global scientific research – including drug discovery. Read more about #AlphaFold 3 in our joint blog with Google DeepMind here: bit.ly/44yfaCw To explore the potential of AlphaFold 3 for drug discovery, Isomorphic labs is applying the model to real-world therapeutic challenges on our internal pipeline projects and pharma partnership programs. Our teams can now create and test hypotheses at the atomic level, and produce highly accurate structure predictions within seconds, standing in stark contrast to the months, or even years, required to experimentally determine answers to similar questions. Through deep integration of this next generation AlphaFold with other breakthrough AI models developed at Isomorphic Labs, we’ll be able to take novel approaches to drug design. Find out more: bit.ly/4a5o3EM
-
Looking forward to seeing you at #ICLR2024 in Vienna next week. Talk to us about our open roles, and AI powered drug discovery @IsomorphicLabs Register your interest here bit.ly/4a2cnCA #ai #machinelearning #drugdiscovery
-
-
Join Max Jaderberg & Sergei Yakneen from Isomorphic Labs to explore how machine learning accelerates biotech and drug discovery. Listen or watch now: lnk.to/GDpc9T8b #GradientDissent #AI #drugdiscovery
-